Combined postoperative radiotherapy and Weekly Cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial

• Published in: International journal of radiation oncology, biology, physics Vol. 36; no. 5; pp. 999 - 1004
• Main Authors: Bachaud, Jean-Marc, Cohen-Jonathan, Elizabeth, Alzieu, Claude, David, Jean-Marc, Serrano, Elie, Daly-Schveitzer, Nicolas
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01.12.1996; Elsevier
• Subjects: Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - therapy; Cisplatin; Cisplatin - therapeutic use; Combination chemotherapy-radiotherapy; Combined Modality Therapy; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Head and neck cancer; Head and Neck Neoplasms - mortality; Head and Neck Neoplasms - therapy; Humans; Medical sciences; Neoplasm Recurrence, Local; Pharmacology. Drug treatments; Prospective Studies; Radiosensitization; Radiotherapy; Regression Analysis; Combination chemotherapy-radiotherapy; Head and neck cancer; Radiosensitization; Radiotherapy; Cisplatin; Human; Postoperative; Squamous cell carcinoma; Treatment efficiency; Malignant tumor; Chemotherapy; Weekly; Head and neck; ENT disease; Advanced stage; Combined treatment; Survival curve; Platinum II Complexes
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/S0360-3016(96)00430-0

Purpose: To report the final results of a prospective randomized trial that aimed to evaluate efficacy and toxicity of concomitant postoperative radiotherapy and Cisplatin infusion in patients with Stage III or IV squamous cell carcinoma of the head and neck histological evidence of extracapsular spread of tumor in lymph node metastases(s). Methods and Materials: Radiotherapy was delivered using a daily dose of 1.7 Gy for the first 54 Gy and 1.8 to 2 Gy until the completion of the treatment. Cisplatin 50 mg i.v. with forced hydratation was given or not every week (i.e., seven to nine cycles) concurrently with radiotherapy. A total of 44 patients were treated by irradiation only (RT group) and 39 by irradiation with chemotherapy (CM group). Results: The RT group displayed a higher rate of loco-regional failures as compared to CM group (41 vs. 23%; p = 0.08). The overall survival, the survival corrected for deaths by intercurrent disease, and the disease-free survival were better in CM group as compared to RT group with statistically significant differences. Survival without loco-regional treatment failure was better in the CM group, the difference being close to the level of significance (p = 0.05). Survival without distant metastases were comparable in the two therapeutic groups. Ten severe late complications were observed, four in the RT group (17%) and six in the CM group (22%). Cox univariate analysis comfirned the importance of the therapeutic modality in predicting the overall surviva, the survival corrected for deaths by intercurrent disease, and the disease-free survival. Conclusions: The present final report of this phase III study confirms preliminary results. The concomitant use of 50 mg weekly Cisplatin infusion and postoperative radiation improved loc-regional control and survival. No significant increase of laet radiation complications was observed in the CM group.